Key Indian Panel Go-Ahead For Novartis’ Kisqali
Executive Summary
Just months after the US FDA cleared Kisqali, Novartis appears on course to bring the breast cancer therapy to India after a key local expert panel recommended the product for marketing in the country, though the filing route through a local Sandoz company has raised some questions.